

Journal: *Drug Metabolism & Disposition*

Article: DMD-AR-2024-001643

Development and verification of a full physiologically-based pharmacokinetic model for sublingual buprenorphine in healthy adult volunteers that accounts for nonlinear bioavailability

Matthijs W. van Hoogdalem, Ryota Tanaka, Trevor N. Johnson, Alexander A. Vinks, Tomoyuki Mizuno

Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA (M.W.v.H., R.T., A.A.V., T.M.); James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA (M.W.v.H.); Certara UK Limited, Sheffield, UK (T.N.J.); Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA (A.A.V., T.M.); Center for Addiction Research, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA (A.A.V., T.M.)

Table S2. Predicted and observed buprenorphine bioavailability following administration of sublingual solutions.

Clinical trial	Route of administration		F
Mendelson et al., 1997	sublingual, solution (3 min hold)	Predicted	0.30
		Observed	0.39
		P/O ratio	0.76
Mendelson et al., 1997	sublingual, solution (5 min hold)	Predicted	0.30
		Observed	0.36
		P/O ratio	0.83
Kuhlman et al., 1996	sublingual, solution	Predicted	0.26
		Observed	0.26
		P/O ratio	1.01
		Geo. Mean ^a	0.86
		(95%CI)	(0.74-0.98)

F, bioavailability; P/O ratio, fold-difference between predicted and observed values.

^aGeometric mean of P/O ratios.